Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
SAKAR Stock Chart & Stats
₹406.55
-₹0.50(-0.17%)
At close: 4:00 PM EST
₹406.55
-₹0.50(-0.17%)
Day’s Range― - ―
52-Week Range₹220.41 - ₹577.95
Previous CloseN/A
Volume6.75K
Average Volume (3M)19.08K
Market Cap
₹11.31B
Enterprise Value₹12.15B
Total Cash (Recent Filing)₹2.16M
Total Debt (Recent Filing)₹718.62M
Price to Earnings (P/E)22.2
Beta0.56
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.61
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.79
Price to Sales (P/S)2.88
P/FCF Ratio-37.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹605.00Price Target Upside48.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSakar has delivered roughly 15% annual revenue growth across recent years, evidencing durable demand and distribution reach in domestic and export markets. Sustained top-line expansion supports scale economies, broader product adoption and provides a foundation for margin recovery and reinvestment over the next several quarters.
Improving EBIT MarginThe jump in EBIT margin to 16.2% reflects stronger operational efficiency or favorable product mix. An expanding operating margin is a durable indicator that core profitability is improving, which can sustainably boost earnings capacity and internal funding for growth if the company maintains cost controls and pricing discipline.
High Operating Cash ConversionAn OCF-to-net-income ratio above 1 indicates earnings are being converted into cash reliably, signifying earnings quality and operational cash generation. Over 2-6 months this supports working capital needs and investment flexibility, reducing reliance on external financing if maintained alongside improving margins.
Bears Say
Sharp Gross Margin CompressionA near-halving of gross margin is a structural concern that materially reduces the buffer to cover SG&A and other operating costs. If driven by cost inflation, pricing pressure or mix shifts, recovery could be slow; lower gross margins impair long-term profitability and limit the durability of operating leverage benefits.
Negative Free Cash FlowPersistent negative free cash flow, even with improvement, constrains the company's ability to self-fund capex, repay debt or return capital. Over several months this necessitates external funding or divestments to support growth; it raises execution risk if cash generation does not turn positive as margins normalize.
Modest Net Profit MarginA sub-10% net margin indicates limited bottom-line conversion after operating costs, reducing resilience to market shocks and limiting retained earnings for reinvestment. Combined with gross margin pressure, modest net margins constrain capacity to build reserves, pay down debt, or fund strategic initiatives over time.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹220.41 and its highest was ₹577.95 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹11.31B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is May 15, 2026 which is in 38 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on Feb 05, 2026. The company reported ₹4.606 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.606.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Undervalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.606 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.088%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
SAKAR Stock 12 Month Forecast
Average Price Target
₹605.00
▲(48.81% Upside)
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Kilitch Drugs (India) Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―